Interés de los péptidos natriuréticos en cardiología veterinaria
Keywords:
Péptidos Natriureticos en cardiología caninosAbstract
The natriuretic peptides are a family of hormones that play a primary role in the regulation of the cardiovascular and renal homeostasis. Three have been identified: the atrial natriuretic peptide (ANP), B type natriuretic peptide (BNP) and C type natriuretic peptide (CNP). The ANP and BNP are synthesized in the atrial and the ventricular cardiac tissue, respectively. In humans, they were related with cardiac and renal disease, hypertension, age and sex. In the same way, in canines and felines were also related with different cardiac pathologies, renal disease, hypertension, obesity . At present, they are considered a complementary tool in the diagnosis, treatment and prognosis in companion animal’s patients with cardiac disease. The objective of the present work was to carried out a bibliographic review among the actual natriuretic peptides available in the field of veterinary cardiology.
Downloads
Metrics
References
Wilkins MR, Redondo J, Brown LA. The natriureticpeptide family. Lancet. 1997;349:1307-1310.
Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:312-328.
Turk JR. Physiologic and patjophysiologic effects of natriuretic peptides and their implications in cardiopulmonary disease. J Am Vet Med Assoc. 2000;216:1970-1976.
Sisson DD. Neuroendocrine evaluation of cardiac disease. Vet Clin North Am Small Anim Pract. 2004;34:1105-1026.
Boerrigter G, Costello-Boerrigter LC, Harty GJ, et al. Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. Am J Physiol Regul Integr Comp Physiol. 2007;292:R897-R901.
Boerrigter G, Burnett JC Jr. Recent advances in natriuretic peptides in congestive heart failure. Expert Opin Investig Drugs. 2004;13:643-652.
Tamura N, Ogawa Y, Chusho H, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA. 2000;97:4239-4244.
De Bold AJ, Borenstein HB, Veress AT, Sonnenberg A. A rapid and potent natriurético response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981;28:89-94.
Oikawa S, Imai M, Ueno A, et al. Cloning and sequence analysis of polypeptide. Nature. 1984;309:724-726.
Saito Y, Nakao K, Itoh H, et al. Brain natriuretic peptide is a novel cardiac hormone. Biochem Biophys Res Commun. 1989;158:360-368.
Sudoh T, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide familiy identified in porcine brain. Biochem Biophys Res Commun. 1990;168:863-870.
De Bold AJ. Tissue fractionation studies on the relationship between an atrial natriuretic factor and specific atrial granules. Can J Physiol Pharm. 1982;60:324-330.
Canaff L, Brechler V, Reudelhuber TL, et al. Secretory granule targeting of atrial natriuretic peptide correlates with its calcium-mediated aggregation. Proc Nat Acad Scie Unit Sta Am. 1996;93:9483-9487.
Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988;332:78-81.
Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans: evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 991;87:1402-1412.
Magga J, Vuolteenabo O, Tokola H, et al. Involvement of transcriptional and posttranscriptional mechanisms in cardiac overload-induced increase of type natriuretic peptide gene expression. Circ Res. 997;81:694-702.
Asano K, Murakami M, Endo D, et al. Complementary DNA cloting, tissue distribution, and synthesis of canine brain natriuretic peptide. Am J Vet Res. 1999;60:860-864.
Clavell A, Stingo A, Wei CM, et al. C-type natriuretic peptide: a selective cardiovascular peptide. Am J Physiol Reg Integrative Comp Physiol. 1993;264:R290- R295.
Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90:195-203.
Schellenberger U, O´Rear J, Guzzetta A, et al. The precursor to B-type natriuretic peptide is an O-linked glycoprotein. Arch Biochem Biophys. 2006;451:160-166.
Giuliani I, Rieunier F, Larue C, et al. Assay for measurement of intact B-type natriuretic peptide prohormona in blood. Clin Chem. 2006;52:1054-1061.
Liang F, O´Rear J, Schellenberger U, et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol. 2007;49:1071-1078.
Yan W, Wu F, Morser J, Wu Q. Corin, a transmembrane cardiac serine protease, acts as pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acadi USA. 2000;97:8525:8529.
Hooper JD, Scarman AL, Clarke BE, et al. Localization of the mosaic transmembrane serine protease corin to heart myocytes. Eur J Biochem. 2000;267;6931-6937.
Seilhamer JJ, Arfsten A, Miller JA, et al. Human and canine gene homologs of porcine brain natriuretic peptide. Biochem Biophys Res Commun. 1989;165:650-658.
Goetze JP. Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. Clin Chem. 2004;50:1503-1510.
Shimizu H, Masuta K, Aono K, et al. Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta. 2002;316:129-135.
Goetze JP, Rehfeld JF, Videbeck R, et al. B-type natriuretic peptide and its precursor in cardiac venous blood from filing hearts. Eur Heart Fail. 2005; 7:69-74.
Maack T. The broad homeostatic role of natriuretic peptides. Arquivos brasileiros de endocrinología e metabología. 2006;50:198-207.
Hogenhuis J, Voors AA, Jaarsma T, et al. Anemia and renal dysfunction are independently associated with BNP and Nt-proBNP levels in patients with heart failure. Eur J Heart Fail. 2007;9:787-794.
Brandt I, Lambeir AM, Ketelslegers JM, et al. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-serine form. Clin Chem. 2006;52:82-87.
Sabrane K, Kruse MN, Fabritz I, et al. Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide. J Clin Invest. 2005;115:1666-1674.
Cataliotti A, Schirger JA, Martin FL, et al. Oral human brain natriuretic peptide actives cyclic guanosine 3´5´-monophosphate and decreases mean arterial pressure. Circulation. 2005;112:836-840.
Koller K, Goeddel D. Molecular biology of the natriuretic peptide and their receptors. Circulation. 1992;86:1081-1088.
Richards AM. The rennin-angiotensin-aldosterone system and the cardiac natriurético peptides. Heart. 1996;76:36-44.
Holtwick R, Gotthardt M, Skrybin B, et al. Smooth muscle-selective deletion of guanylyl cyclase-A prevents the acute but not chronic effects of ANP on blood pressure. Proc Natl Acad Sci USA. 2002;99:7142-7147.
Maack T, Suzuki M, Almeida FA, et al. Physiological role of silent receptors of atrial natriurético factor. Sci. 1987;238:675-678.
Almeida FA, Suzuki M, Scarborough RM, et al. Clearance function of type C receptors of atrial natriuretic peptide factor in rats. Am J Physiol. 1989;256:469-475.
Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, Ctype natriuretic peptide and some C-receptor ligands by endopetidase-24-11. Biochem. 1993;291:83-88.
Ozaki J, Shimizu H, Hashimoto Y, et al. En-zymatic inactivation of major circulating forms of atrial and brain natriuretic peptides. Eur J Pharmacol. 1999;370:307-312.
Zhou HL, Fiscus RR. Brain natriuretic peptide (BNP) causes endothelium-independt relaxation and elevation of cyclic GMP in rat thoracic aorta. Neuropeptides. 1989; 14:161-169.
Kuhn M. Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A. Circ Res. 2003;93:700-709.
Kuhn M. Molecular physiology of natriuretic peptide signaling. Basic Res Cardiol. 2004;99:76-82.
Koller KJ, Lowe DG, Bennett GI, et al. Selective activation of the B natriuretic peptide receptor by Ctype natriuretic peptide (CNP). Sciencie. 1991;252:120-123.
Takimoto E, Champion HC, Li M, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005;11:214-222.
Luchner A, Hengstenberg C, Lowel H, et al. Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP. Hypertension. 2005;46:118-123.
McDowell G, Patterson C, Maguire S, et al. Variability of Nt-proANP and C-ANP. Eur J Clin Invest. 2002;32:545-548.
Fontana M, Zyw L, Poletti R, et al. Improved early diagnosis of heart failure with B-type natriuretic peptides: comparison between BNP and Nt-proBNP diagnostic accuracy. Eur J Heart Fail. 2007;6,14.
Pemberton CJ, Johnson ML, Yandle TG, et al. Deconvolution analysis of cardiac natriuretic peptides during acute volume overload. Hypertension. 2000;36:355-359.
Roncon-Albuquerque R, Vasconcelos M, Lourenco AP, et al. Acute changes of biventricular gene expression in volumen and right ventricular pressure overload. Life Sci. 2006;78:2633-2642.
Luchner A, Muders F, Dietl O, et al. Differential expression of cardiac ANP and BNP in a rabbit model of progressive left ventricular dysfunction. Cardiovasc Res. 2001;51:601-607.
Maeda K, Tsutamoto T, Wada A, et al. Insufficient secretion of atrial natriuretic peptide at acute phase of myocardial infarction. J Appl Physiol. 2000;89:458-464.
Luchner A, Stevens TL, Borgeson DD, et al. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol. 1998;247:H1684-H1689.
Moro C, Berlan M. Cardiovascular and metabolic effects of natriuretic peptides. Fundam Clin Pharmacol. 2006;20:41-49.
Moe GW, Grima EA, Wong NL, et al. Plasma and cardiac tissue atrial and brain natriuretic peptides in experimental heart failure. J Am Coll Cardiol.1996;27:720-727.
Ma KK, Banas K, de Bolt AJ. Determinants of inducible brain natriuretic peptide promoter activity. Regul Pept. 2005;128:169-176.
Rodeheffer RJ. Measuring plasma B-type natriuretic peptide in heart failure. J Am Coll Cardiol. 2004;44:740-749.
Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation. 2002;105;2392-2397.
Goetze JP, Kastrup J, Rehfeld JF. The paradox of increaser natriuretic hormones in congestive heart failure patients: does the endocrine heart also fail in heart failure. Eur Heart J. 2003;24:1471-1472.
Oyama MA, Fox PR, Rush JE, et al. Clinical utility of serum N-terminal pro-B-type natriuretic peptide concentration for identifying cardiac disease in dogs and assessing disease severity. J Am Vet Med Assoc. 2008;232:1496-1503.
Schellenberg S, Grenacher B, Kaufmann K, et al. Analytical validation of commercial immunoassays for the measurement of cardiovascular peptides in the dogs. Vet J. 2008;178:85-90.
Bucley MG, Marcus NJ, Yacoub MH. Cardiac peptide stability, aprotinin and room temperature: Importance for assessing cardiac function in clinical practice. Cli Sci (London). 1999;97:689-695.
Thomas CJ, Woods RL. Haemodynamic action of B-type natriuretic peptide substantially outlasts its plasma half-life in conscious dogs. Clin Exp Pharmacol Physiol. 2003;30:369-372.
Blonde L, Wehmann RE, Steiner AL. Plasma clearance rates and renal clearance of 3H-labeled cyclic AMP and 3H-labeled cyclic GMP in the dog. J Clin Invest. 1974;53:163-172.
Kellihan HB, Oyama MA, Reynols CA, et al. Weekly variability of plasma and serum Nt-proBNP measurements in normal dogs. J Vet Cardiol. 2009;11:593-597.
Boswood A, Dukes-McEwan J, Loureiro J, et al. The diagnostic accuracy of different natriuretic peptide
in the investigation of canine cardiac disease. J Small Anim Pract. 2008;49:26-32.
Liu ZL, Wiedmeyer CE, Sisson DD, Solter PF. Cloning and characterization of feline brain natriuretic peptide. Gene. 2002;292:183-190.
Oikawa S, Imai M, Inuzuka C, et al. Structure of dog and rabbit precursors of atrial natriuretic polypeptides deduced from nucleotide sequence of cloned cDNA. Biochem Biophys Res Commun. 1985;132:892-899.
Biondo AW, Liu ZL, Wiedmeyer CE, et al. Genomic sequence and cardiac expression of atrial natriureticpeptide in cats. Am J Vet Res. 2002;63:236-240.
Doust JA, Glasziou PP, Pietrzak E, et al. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med. 2004;164:1978-1984.
Swedberg K, Cleland J, Dargie H, et al. Guidelinesfor the diagnosis and treatment of chronic heart failure:executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:1115-1140.
Takase H, Toriyama T, Sugiura, et al. Brain natriuretic peptide detects cardiac abnormalities in mass screening. Eur J Clin Invest. 2007;37:257-262.
Issac Dl. Biomarkers in heart failure management. Curr Opin Cardiol. 2008;23:127-133.
Silver MA, Maisel A, Yancy CW, et al. Consensus Panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptide in cardiovascular disease. Congest Heart Fail. 2004;10(3):1-30.
Doust JA, Pietrzak E, Dobson A, et al. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure. Systematic Review. BMJ. 2005;330:625-633.
Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guide therapy to improve outcome in heart failure: the STARS BNP Multicenter Study. J Am Coll Cardiol. 2007;49:1733-1739.
Mueller C, Breidthardr T, Laule-Kilian K, et al. The integration of BNP and Nt-proBNP into clinical medicine. Swiss Med Whly. 2007;134:4-12.
Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358:2148-2159.
Hinderliter AL, Blumenthal JA, O´Conner C, et al. Independent prognostic value of echocardiography and N-terminal pro-B-type natriuretic peptide in patients with heart failure. Am Heart J. 2008;156:1191-1195.
Vollmar AM, Reusch C, Kraft W, et al. Atrial natriuretic peptide concentration in dogs with congestive heart failure, chronic renal failure, and hyperadrenocorticism. Am J Vet Res. 1991;52:1831-1834.
Greco DS, Biller B, Van Liew CH, et al. Measurement of plasma atrial natriuretic peptide as an indicator of prognosis in dogs with cardiac disease. Can Vet J. 2003;44:293-297.
MacDonald KA, Kittleson MD, Munro C, et al. Brain natriuretic peptide concentration in dogs with heart disease and congestive heart failure. J Vet Intern Med. 2003;17:172-177.
Oyama MA, Sisson DD, Solter PF. Prospective screening for occult canine dilated cardiomyopathy using B-type and atrial natriuretic peptide and cardiac troponin-I assay. J Vet Intern Med. 2005;19:195-196.
Haggstrom J, Hansson K, Karlberg BE, et al. Plasma concentration of atrial natriuretic peptide in relation to severity of mitral regurgitation in Cavalier King Charles Spaniels. Am J Vet Res. 1994;55:698-703.
Haggstrom J, Hansson K, Kvart C, et al. Effects of naturally acquired decompensated mitral valve regurgitation on the rennin-angiotensin-aldosterone system and atrail natriuretic peptide concentration in dogs. Am J Vet Res. 1997;58:77-82.
Haggstrom J, Hansson K, Kvart C, et al. Relationship between different natriuretic peptide and severity of naturally acquired mitral regurgitation in dogs with chronic myxomatous mitral valve disease. J Vet Cardiol. 2000;2:7-16.
Prosek R, Sisson DD, Oyama MA, et al. Distinguishing cardiac and non-cardiac dyspnea in 48 dogsvia plasma atrial natriuretitc factor, B-type natriuretic factor, endotelina, and cardiac troponin-I. J Vet Intern Med. 2007;21:238-242.
Fine DM, Declue AE, Reinero CR. Evaluation of circulating amino terminal-pro-B-type natriuretic peptide concentration in dogs with respiratory distress attributable to congestive heart failure or primary pulmonary disease. J Am Vet Med Assoc. 2008;232:1674-1679.
Takemura N, Toda N, Miyagawa Y, et al. Evaluation of Plasma N-Terminal Pro-Brain natriuretic Peptide (Nt-proBNP) Concentrations in Dogs with Mitral Valve Insufficiency. J Vet Med Sci. 2009;71(7):925-929.
Tarnow I, Olsen LH, Kvart C, et al. Predictive value of natriuretic peptides in dogs with mitral valvule disease. Vet J. 2009;180:195-201.
Forfia PR, Lee M, Tunin RS, et al. Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-tipe natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol. 2007;49:1079-1088).
Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptide, their receptors and cGMP-dependent signaling functions. Endocr Rev. 2006;27:47-72.
Baumwart RD, Meurs KM. Assessment of plasma brain natriuretic peptide concentration in Boxers with arrhythmogenic right ventricular cardiomyopathy. Am J Vet Res. 2005;66:2086-2089.
O´Sullivan ML, O´Grady MR, Minors SL. Plasma big endothelin-1, atrial natriuretic peptide, aldosterone, and norepinephrine concentrations in normal Doberman Pinschers and Doberman Pinschers with dilated cardiomyopathy. J Vet Intern Med. 2007;21:92-99.
Oyama MA, Sisson DD, Solter PF. Prospective screening for occult cardiomyopathy in dogs by measurement of plasma atrial natriuretic peptide, B-type natriuretic peptide, and cardiac troponin-I concentrations. Am J Vet Res. 2007;68:42-47.
Chetboul V, Tessier-Vetzel D, Escriou C, et al. Diagnostic potential of natriuretic peptides in the occult phase of Golden retriever muscular dystrophy cardiomyopathy. J Vet Intern Med. 2004;18:845-850.
Hori Y, Tsubaki M, Katou A, et al. Evaluation of Nt-proBNP and CT-ANP as Markers of concentric hypertrophy in dogs with a model of compensated aortic stenosis. J Vet Intern Med. 2008;22:1118-1123.
Iwanaga Y, Nishi I, Furuichi S, et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol. 2006;47:742-748.
Leya FS, Arab D, Joyal D, et al. The efficacy of brain natriuretic peptide levels in differentiating constrictive pericarditis from restrictive cardiomyopathy. J Am Coll100. Connlolly DJ, Soares Magalhaes RJ, Luis Fuentes V, et al. Circulating natriuretic peptide concentrations in cats with respiratory distress [abstract]. J Vet Intern Med. 2008;22:719-720.
Connolly DJ, Soares Magalhaes RJ, Syme HM, et al. Circulating Natriuretic Peptides in Cats with Heart Disease. J Vet Intern Med. 2008;22:96-105.
Biondo AW, Ehrhart EJ, Sisson DD, et al. Immunohistochemitry of atrial and brain natriuretic peptides in control cats and cats with hypertrophy cardiomyopathy. Vet Pathol. 2003;40:501-506.
McGrath MF, de Bold ML, de Bold AJ. The endocrine function of the heart. Trends Endocrinol Metab. 2005;16:469-477.
Sisson DD, Oyama MA, Solter PF. Plasma levels of ANP, BNP, epinephrine, norepinephrine, serum aldosterone, and plasma rennin activity in healthy cats and cats with myocardial disease. J Vet intern Med. 2003;17:483-486.
Poutanen T, Tikanoja T, Jaaskelainen P, et al. Diastolic dysfunction without left ventricular hypertrophy is an early finding in children with hypertrophic cardiomyopathy-causing mutations in the beta-myosin heavy chain, alpha-tropomyosin, and myosin binding protein C genes. Am Heart J. 2006;151:725-729.
Fox PR, Oyama MA, MacDonald K, et al. Comparison of Nt-proBNP concentration in cats with acute dyspnea from cardiac or respiratory disease [abstract]. J Vet Intern Med. 2008;22:719.
Fox PR, Oyama MA, Reynolds C, et al. Utility of plasma N-terminal pro-brain natriuretic peptide (NTproBNP) to distinguish between congestive heart failure and non-cardiac causes of acute dyspnea in cats. J Vet Cardiol. 2009;11:S51-S61.
Nishida Y, Morita H, Minamino N, et al. Effects of brain natriuretic peptide on hemodynamic and renal function in dogs. Japan J Physiol. 1990;40:531-540.
Lalor SM, Connolly DJ, Elliott J, et al. Plasma concentrations of natriuretic peptides in normal cats and normotensive and hypertensive cats with chronic kidney disease. J Vet Cardiol. 2009;11:71-79.
Mueller C, Laule-Kilian K, Scholer A, et al. B-type natriuretic peptide for acute dyspnea in patients with kidney disease: Insights from a randomized comparison. Kidney Int. 2005;67:278-284.
Mark PB, Stewart GA, Gansevoort RT, et al. Diagnostic potential of circulating natriuretic peptides in chronic kidney disease. Nephrol Dial Transplant. 2006;21:402-410.
Anwaruddin S, Lloyd-Jones DM, Baggish A, et al. Renal function, congestive heart failure, and aminoterminal pro-brain natriuretic peptide measurement. Results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol. 2006;47(1):91-97.
De Filippi C, Can Kimmenade RR, Pinto YM. Amino-terminal pro-B-type natriuretic peptide testing in renal disease. Am J Cardiol. 2008;101(Suppl.):82A114. Sudoh M, Gustafsson F, Kistorp CN, et al. Effects of body mass index and age on N-terminal pro-brain natriuretic peptide are associated with glomerular filtration rate in chronic heart failure patients. Clin Chem. 2007;53:1928-1935.
Eriksson AS, Jarvinen AK, Eklund KK, et al. Effect of age and body weigth on neurohumoral variables in healthy Cavalier King Charles Spaniels. Am J Vet Res. 2001;62:1818-1824.
Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide concentration: impact
of age and gender. J Am Coll Cardiol. 2002;40:976-982.
Raymond I, Groenning BA, Hildebrandt, et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart. 2003;89:745-751.
Koch AM, Rauh M, Zinc S, et al. Decreasing ratio of plasma N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide according to age. Acta Paediatr. 2006;95:805-809.
Bayes-Genis A, De Filippi C, Januzzi Jr JL. Understanding amino-terminal pro-B-type natriuretci peptide in obesity. Am J Cardiol. 2008;101:89-94.
Mlezid´Eril G, Tagnochetti T, Nauti A, et al. Biological variation of N-terminal pro-brain natriuretic peptide in healthy individuals. Clin Chem. 2003;49:1554-1555.
O´Hanlon R, O´Shea P, Ledwidge M, et al. The biologic variability of B-type natriuretic peptide and Nterminal pro-B-type natriuretic peptide in stable heart failure patients. J Cardiol Fall. 2007;13:50-55.
Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of descompensated congestive heart failuire. N Engl J Med. 2000;343:246-253.
Chen HH, Grantham JA, Chirger JA, et al. Subcutaneous administration of brain natriuretic peptide in experimental heart failure. J Am Coll Cardiol. 2000;36:1706-1712.
Chen HH, Huntley BK, Schirger JA, et al. Maximizing the renal cyclic 3´5´-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: A novel strategy to improve renal function in experimental overt heart failure. J Am Soc Nephrol. 2006;17(10):2742-2747.
Lainchbury JG, Burnnett JC Jr, Meyer D, et al. f fects of natriuretic peptides on load and myocardial function in normal and heart failure dogs. Am J Physiol eart Circ Physiol. 2000;278:H33-40.
Downloads
Published
How to Cite
Issue
Section
License
Authors retain the copyright and assign to the journal the right of the first publication, with the with the terms of the Creative Commons attribution license. This type of license allows other people to download the work and share it, as long as credit is granted for the authorship, but does not allow them to be changed in any way or used them commercially.
Analecta Veterinaria by School of Veterinary Sciences, National University of La Plata is distributed under a Creative Commons Attribution-NonCommercial-NoDeriv 4.0 International License.
